PHGE
BiomX Inc. AMEX Listed Mar 13, 2019$0.62
Mkt Cap $980,840
52w Low $0.61
0.1% of range
52w High $14.71
50d MA $3.56
200d MA $6.21
P/E (TTM)
-0.0x
EV/EBITDA
-3.9x
P/B
—
Debt/Equity
-1.1x
ROE
2780.3%
P/FCF
-4.9x
RSI (14)
—
ATR (14)
—
Beta
1.70
50d MA
$3.56
200d MA
$6.21
Avg Volume
153.1K
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
22 Einstein Street · Ness Ziona, DE 7414003 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -4.61 | -4.61 | +0.0% | 4.86 | +0.8% | +0.6% | -3.7% | -1.9% | -2.8% | -16.5% | — |
| Nov 12, 2025 | AMC | -6.08 | -5.51 | +9.4% | 7.15 | +2.9% | -7.0% | +7.5% | -15.9% | -10.6% | -5.2% | — |
| Aug 13, 2025 | AMC | -0.33 | 0.19 | +157.6% | 9.43 | -0.7% | +1.4% | +10.9% | -6.4% | +4.9% | -5.1% | — |
| May 15, 2025 | AMC | -0.42 | -0.33 | +21.4% | 10.71 | +0.4% | -4.2% | +2.2% | -1.0% | -2.8% | -0.4% | — |
| Mar 25, 2025 | AMC | -1.65 | -1.07 | +35.2% | 11.11 | +0.0% | -11.1% | +7.6% | +1.7% | -2.3% | -11.3% | — |
| Nov 14, 2024 | AMC | -0.60 | -0.97 | -61.7% | 14.25 | +2.7% | -17.3% | -7.0% | +0.5% | -12.2% | -3.4% | — |
| Aug 14, 2024 | AMC | -1.20 | 0.70 | +158.3% | 34.96 | +3.3% | -11.4% | +2.5% | -6.6% | -5.1% | +2.0% | — |
| May 20, 2024 | AMC | -0.70 | -1.50 | -114.3% | 64.98 | +8.2% | +6.7% | -2.2% | -3.4% | -1.4% | +5.9% | — |
| Apr 3, 2024 | AMC | -1.10 | -0.80 | +27.3% | 66.50 | +11.4% | +8.6% | +0.0% | -5.8% | -2.0% | -2.6% | — |
| Nov 14, 2023 | AMC | -1.10 | -1.30 | -18.2% | 73.15 | +3.6% | -1.6% | +8.4% | -0.2% | -9.8% | +8.1% | — |
| Aug 9, 2023 | AMC | -1.20 | -1.20 | +0.0% | 72.39 | +2.4% | -1.3% | -4.5% | +4.7% | +0.3% | -1.9% | — |
| May 15, 2023 | AMC | -2.00 | -2.00 | +0.0% | 56.81 | -3.0% | -11.4% | +4.9% | -0.4% | +1.1% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $6.81 | $7.03 | +3.2% | +9.0% | +1.1% | -16.8% | +2.1% | -2.8% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.78 | $5.20 | -10.0% | -18.7% | -7.2% | -3.0% | +11.1% | -4.0% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.49 | $5.49 | +0.0% | +5.3% | -18.7% | -7.2% | -3.0% | +11.1% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.41 | $10.32 | -0.9% | -5.1% | +4.0% | +1.1% | +0.6% | +1.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.71 | $10.75 | +0.4% | -4.2% | +2.2% | -1.0% | -2.8% | -0.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.13 | $11.40 | +2.4% | -1.0% | +2.6% | -5.9% | -0.1% | -5.5% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.56 | $10.55 | -0.1% | -11.3% | +27.5% | -6.9% | -1.0% | +2.6% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.05 | $14.18 | +0.9% | +3.1% | -5.5% | +2.6% | +2.1% | +0.7% |
| Jan 8 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $15.01 | $15.06 | +0.3% | -6.4% | +3.1% | -5.5% | +2.6% | +2.1% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.01 | $15.06 | +0.3% | -6.4% | +3.1% | -5.5% | +2.6% | +2.1% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.97 | $33.25 | +7.4% | +2.5% | -6.6% | -5.1% | +2.0% | -9.9% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.98 | $70.30 | +8.2% | +6.7% | -2.2% | -3.4% | -1.4% | +5.9% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.10 | $58.90 | +6.9% | +1.7% | +17.6% | -2.0% | -1.2% | +4.2% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.96 | $77.90 | +6.8% | -8.9% | +8.6% | +0.0% | -5.8% | -2.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $130.72 | $117.80 | -9.9% | -41.9% | +6.8% | -9.4% | -4.4% | +5.4% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.10 | $72.20 | -2.6% | -1.3% | -1.6% | +8.4% | -0.2% | -9.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.01 | $57.00 | +7.5% | +7.2% | -11.4% | +4.9% | -0.4% | +1.1% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $61.75 | $66.50 | +7.7% | +0.0% | -3.7% | -13.1% | -4.4% | -3.8% |
| May 24 | Chardan Capital | Maintains | Buy → Buy | — | $152.00 | $171.00 | +12.5% | +8.8% | -7.8% | -4.7% | -5.1% | -7.6% |
| May 12 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $171.00 | $158.27 | -7.4% | -5.1% | -7.5% | +0.0% | +4.4% | +0.7% |
| Nov 16 | Chardan Capital | Maintains | Buy → Buy | — | $450.30 | $440.80 | -2.1% | -7.6% | -2.3% | -7.5% | +0.5% | -6.0% |
| Oct 19 | Chardan Capital | Maintains | Buy → Buy | — | $404.70 | $412.30 | +1.9% | +15.0% | -2.4% | -1.3% | -3.4% | -1.3% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $461.70 | $412.30 | -10.7% | -12.3% | +15.0% | -2.4% | -1.3% | -3.4% |
| Apr 15 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $1212.20 | $1295.80 | +6.9% | +5.6% | -5.6% | +0.5% | -1.7% | +4.3% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1121.00 | $1174.20 | +4.7% | +3.9% | +1.1% | -3.5% | +2.7% | +2.9% |
| Jan 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1823.05 | $1805.00 | -1.0% | -3.2% | -4.7% | +4.0% | +3.3% | +0.1% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Zorronet secured a commercial contract with Israel Railways for alert station infrastructure and ongoing maintenance services, demonstrating platform validation and providing recurring revenue potential that could drive sustainable growth.
Apr 16
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
HSCC acquired PHGE, potentially expanding its market reach and revenue streams, which investors should monitor for integration execution risks and synergy realization in upcoming quarters.
Apr 13
8-K
Unknown — 8-K Filing
PHGE shareholders overwhelmingly approved adjourning the special meeting if needed, suggesting management retained flexibility for a potentially contentious Proposal 3, which likely passed despite close voting margins.
Apr 10
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Exelon (ESLT) completed acquiring ZorroNet, an Israeli AI defense tech company, expanding its cybersecurity capabilities and revenue streams in a high-growth sector.
Apr 10
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
PHGE signed a $5 million material agreement, indicating a modest revenue opportunity or strategic partnership that could slightly improve financial results, though the small contract size limits near-term stock impact.
Apr 1
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I don't have the specific content of the press release to analyze. To provide an accurate one-sentence assessment of what this means for PHGE's stock, I would need details about what matters were disclosed—such as earnings results, product approvals, partnerships, or other material events.
Could you share the actual announcement details?
Mar 27
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
PHGE's material agreement with Pyu Pyu Capital LLC likely involves financing or strategic partnership that investors should monitor for details on terms, dilution impact, and whether it strengthens the company's financial position.
Mar 19
8-K
Unknown — 8-K Filing
Pathogen (PHGE) is issuing preferred stock and warrants to new investors while seeking shareholder approval to adjourn its special meeting, signaling potential dilution concerns and governance uncertainty that could pressure near-term stock performance.
Mar 11
8-K · 5.02
!!! Very High
BiomX Inc. -- 8-K 5.02: Executive Change
BiomX (PHGE) experienced significant leadership turnover with CEO Jonathan Solomon and Chairman Russell Greig both resigning, while Amir Shalom joined as a director.
Mar 6
8-K · 5.02
!!! Very High
BiomX Inc. -- 8-K 5.02: Executive Change
BiomX Inc. (PHGE) appointed David Rokach as a director, strengthening its board composition and potentially signaling confidence in the company's strategic direction and governance.
Mar 2
8-K · 5.02
!!! Very High
BiomX Inc. -- 8-K 5.02: Executive Change
BiomX Inc. strengthened its board by appointing Guy Arieli and Shaked Ran as directors while Alan Moses resigned, signaling potential strategic shifts in the phage therapy company's leadership.
Feb 25
8-K · 5.02
!!! Very High
BiomX Inc. -- 8-K 5.02: Executive Change
BiomX Inc. (PHGE) replaced two departing directors with Liat Bidas, signaling potential strategic shifts in board composition and governance.
Feb 13
8-K · 2.01
!!! Very High
BiomX Inc. -- 8-K 2.01: Acquisition Completed
BiomX's Israeli subsidiary filed for insolvency proceedings, signaling financial distress and potential restructuring challenges for the parent company and its shareholders.
Feb 10
Data updated apr 26, 2026 7:34pm
· Source: massive.com